Literature DB >> 25024216

Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein.

Misook Oh1, Ji Hoon Lee2, Wei Wang3, Hui Sun Lee4, Woo Sirl Lee2, Christopher Burlak5, Wonpil Im4, Quyen Q Hoang6, Hyun-Suk Lim7.   

Abstract

Pharmacological chaperones are small molecules that bind to proteins and stabilize them against thermal denaturation or proteolytic degradation, as well as assist or prevent certain protein-protein assemblies. These activities are being exploited for the development of treatments for diseases caused by protein instability and/or aberrant protein-protein interactions, such as those found in certain forms of cancers and neurodegenerative diseases. However, designing or discovering pharmacological chaperones for specific targets is challenging because of the relatively featureless protein target surfaces, the lack of suitable chemical libraries, and the shortage of efficient high-throughput screening methods. In this study, we attempted to address all these challenges by synthesizing a diverse library of small molecules that mimic protein α-helical secondary structures commonly found in protein-protein interaction surfaces. This was accompanied by establishing a facile "on-bead" high-throughput screening method that allows for rapid and efficient discovery of potential pharmacological chaperones and for identifying novel chaperones/inhibitors against a cancer-associated protein, myeloid cell leukemia 1 (MCL-1), and a Parkinson disease-associated protein, α-synuclein. Our data suggest that the compounds and methods described here will be useful tools for the development of pharmaceuticals for complex-disease targets that are traditionally deemed "undruggable."

Entities:  

Keywords:  chemical biology; drug discovery; helical mimetic

Mesh:

Substances:

Year:  2014        PMID: 25024216      PMCID: PMC4121809          DOI: 10.1073/pnas.1320556111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  65 in total

Review 1.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

2.  Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

Authors:  Raquel L Lieberman; Brandon A Wustman; Pedro Huertas; Allan C Powe; Corey W Pine; Richie Khanna; Michael G Schlossmacher; Dagmar Ringe; Gregory A Petsko
Journal:  Nat Chem Biol       Date:  2006-12-24       Impact factor: 15.040

3.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors:  Federico Bernal; Andrew F Tyler; Stanley J Korsmeyer; Loren D Walensky; Gregory L Verdine
Journal:  J Am Chem Soc       Date:  2007-02-07       Impact factor: 15.419

Review 4.  BCL-2 family antagonists for cancer therapy.

Authors:  Guillaume Lessene; Peter E Czabotar; Peter M Colman
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

5.  A new type of synthetic peptide library for identifying ligand-binding activity.

Authors:  K S Lam; S E Salmon; E M Hersh; V J Hruby; W M Kazmierski; R J Knapp
Journal:  Nature       Date:  1991-11-07       Impact factor: 49.962

Review 6.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

7.  A systematic method for identifying small-molecule modulators of protein-protein interactions.

Authors:  Alexander R Horswill; Sergey N Savinov; Stephen J Benkovic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-21       Impact factor: 11.205

8.  Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides.

Authors:  Nathaniel P Chongsiriwatana; James A Patch; Ann M Czyzewski; Michelle T Dohm; Andrey Ivankin; David Gidalevitz; Ronald N Zuckermann; Annelise E Barron
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Beta-peptidic peptidomimetics.

Authors:  Dieter Seebach; James Gardiner
Journal:  Acc Chem Res       Date:  2008-06-26       Impact factor: 22.384

10.  What are pharmacological chaperones and why are they interesting?

Authors:  Dagmar Ringe; Gregory A Petsko
Journal:  J Biol       Date:  2009-10-13
View more
  19 in total

Review 1.  The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders.

Authors:  Diego E Berman; Dagmar Ringe; Greg A Petsko; Scott A Small
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 2.  Assay strategies for identification of therapeutic leads that target protein trafficking.

Authors:  P Michael Conn; Timothy P Spicer; Louis Scampavia; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

3.  Pharmacological chaperones in the age of proteomic pathology.

Authors:  Scott A Small
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-13       Impact factor: 11.205

4.  Asymmetric synthesis of vinylogous β-amino acids and their incorporation into mixed backbone oligomers.

Authors:  Hao Wu; Hongchan An; Shuting Cynthia Mo; Thomas Kodadek
Journal:  Org Biomol Chem       Date:  2017-04-11       Impact factor: 3.876

5.  The non-detergent sulfobetaine-201 acts as a pharmacological chaperone to promote folding and crystallization of the type II TGF-β receptor extracellular domain.

Authors:  Kittikhun Wangkanont; Katrina T Forest; Laura L Kiessling
Journal:  Protein Expr Purif       Date:  2015-06-11       Impact factor: 1.650

6.  Targeting the Side-Chain Convergence of Hydrophobic α-Helical Hot Spots To Design Small-Molecule Mimetics: Key Binding Features for i, i + 3, and i + 7.

Authors:  Zhen Wang; Haitao Ji
Journal:  J Med Chem       Date:  2019-10-22       Impact factor: 7.446

7.  Mimicry of a β-Hairpin Turn by a Nonpeptidic Laterally Flexible Foldamer.

Authors:  Joseph W Meisel; Chunhua T Hu; Andrew D Hamilton
Journal:  Org Lett       Date:  2018-06-13       Impact factor: 6.005

8.  Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.

Authors:  Valeria Azzarito; Philip Rowell; Anna Barnard; Thomas A Edwards; Andrew Macdonald; Stuart L Warriner; Andrew J Wilson
Journal:  Chembiochem       Date:  2016-01-21       Impact factor: 3.164

9.  Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.

Authors:  Wei Wang; Linh T T Nguyen; Christopher Burlak; Fariba Chegini; Feng Guo; Tim Chataway; Shulin Ju; Oriana S Fisher; David W Miller; Debajyoti Datta; Fang Wu; Chun-Xiang Wu; Anuradha Landeru; James A Wells; Mark R Cookson; Matthew B Boxer; Craig J Thomas; Wei Ping Gai; Dagmar Ringe; Gregory A Petsko; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

10.  Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions.

Authors:  Anna Barnard; Kérya Long; Heather L Martin; Jennifer A Miles; Thomas A Edwards; Darren C Tomlinson; Andrew Macdonald; Andrew J Wilson
Journal:  Angew Chem Int Ed Engl       Date:  2015-02-04       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.